Xebra Obtains Trademarks in the European Union

VANCOUVER, BC, January 18, 2022 /CNW/ – Xebra Brands Ltd. (“Xebra”) (CSE: XBRA) (OTCQB: XBRAF) (FSE: 9YC), a cannabis company, is pleased to announce that it has obtained registered trademarks in the European Union, covering 28 countries and 10 territories, for trademarks of Xebra’s THC and CBD infused beverages, including DAZZLING soft drinks and the slogan very crazy, HOLA HI iced teas and the slogan It is high time, HIGHJACK energy drinks and the slogan Have a good trip, VICIOUS CITRUS lemonades and the slogan lemonade for renegades, HIGH CASTLE waters, and the slogan Drink like a king, and Xebra’s CBD Sports Drink TO CONQUER.


At December 1, 2021, Xebra was granted a cannabis injunction by the Mexican Supreme Court, which positions it as a frontrunner in the Mexican CBD and CBG sector. Xebra has also been selected by the Dutch government, from a group of competitive applicants, as one of five companies to compete for two exclusive licenses to cultivate medicinal cannabis (including THC) in the Netherlands, with an initial guaranteed six-year government contract for each winning party, estimated at ~100 million CAD. In Canada, Xebra plans to launch its Vicious Citrous THC lemonade in the spring of 2022. In Colombia, Xebra is completing agronomic evaluations, to fully register cannabis seed varieties, in anticipation of commercial activities in late 2022.

For more information about Xebra, visit our website: xebrabrands.com


Rodrigue Gallardo

For more information contact:

+1 (604) 418-6560
[email protected]

Certain information contained in this press release constitutes forward-looking statements under applicable securities laws. All statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, but are not limited to, statements regarding Xebra Brands Ltd.’s expectations. (the “Company”) regarding: the final decision of the Supreme Court of Mexico granting an injunction to the Company’s wholly-owned subsidiary (the “Injunction”), the receipt of all clearances relating to the Injunction, the Company obtaining a first-mover advantage under the Injunction, other companies cultivating or marketing cannabis in Mexico and the timing and processes thereof, the possibility that the majority of North American industrial-scale cannabis production activity takes place in Mexico, or expectations related to Xebra’s operations; the legalization of cannabis and its derivatives in Mexico; the potential for increased industry-wide cannabis production by Mexico and timing thereof; the export of cannabis products from Mexico; its ability to successfully execute its business plan or business model; its ability to provide economic, environmental, social or benefits of any kind to the communities in which it operates or may operate in the future; its ability to be the first to enter a country, or to obtain or maintain governmental licenses, permits or authorizations generally, or specifically in Mexico, Colombia, Canada, the Netherlands, or elsewhere ; its ability to successfully apply for and obtain trademarks and other intellectual property rights in any jurisdiction; its ability to be cost competitive; its ability to cultivate, cultivate or process hemp or cannabis in Mexico, Colombia, Canada, the Netherlands, or elsewhere and related plans; financial, operational or any other term relating to the Company’s participation in the Dutch medicinal cannabis cultivation trial; its ability to manufacture cannabis beverages, wellness products or other products; its ability to market or sell cannabis beverages, wellness products or other products, in Mexico, Colombia, Canada, the Netherlands, or elsewhere ; its ability to market or sell Vicious Citrus Lemonade in 2022 or at any time in any jurisdiction; its ability to market or sell Elements wellness products in any jurisdiction at any time; its ability to create wellness products with a therapeutic effect or benefit; plans for future growth and direction of the business; financial projections, including expected revenues, gross profit and EBITDA (which is a non-GAAP financial measure); plans to increase product volumes, capacity of existing facilities, supplies from growers and third-party contractors; the expected growth of the cannabis industry generally; management’s expectations, beliefs and assumptions; events or developments that Xebra expects to occur in the future; general economic conditions; and other risk factors described in the Company’s prospectus dated September 30, 2021. All statements, other than statements of historical facts, are forward-looking information and statements. The words “aim”, “believe”, “expect”, “anticipate”, “contemplate”, “target”, “intend”, “continue”, “plans”, “budget”, ” estimate”, “may”, “will” and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based on a number of estimates and assumptions which, although believed to be reasonable by Xebra as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. These factors include, but are not limited to, Xebra’s inability to generate sufficient revenue or raise sufficient funds to carry out its business plan; changes in governmental legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with farming and cultivation activities generally, including inclement weather, access to seed supply, low crop yields and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; the inability to identify, negotiate and complete a potential acquisition for any reason; the ability to retain key employees; reliance on third parties for services and supplies; non-performance by contractual counterparties; general economic conditions; the continued growth in global demand for cannabis products and the continued increase in the number of jurisdictions legalizing cannabis; and timely receipt of regulatory approval for license applications. The preceding list is not exhaustive, and Xebra undertakes no obligation to update or revise any of the foregoing, except as required by law. Many of these uncertainties and contingencies could affect Xebra’s actual performance and cause its actual performance to differ materially from what is expressed or implied by forward-looking statements made by or on behalf of Xebra. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and that actual results and future events could differ materially from those set forth therein.

SOURCEXebra Brands Ltd.

Comments are closed.